New blood tests can detect Alzheimer's disease pathology years before symptoms appear, offering potential for early intervention. pTau217 levels in blood correlate strongly with amyloid plaques in the brain, allowing doctors to identify high-risk individuals. However, these tests remain less accurate in people without cognitive impairment, with a 50/50 chance of false positives. While pTau217 shows 90% accuracy in symptomatic patients, experts caution against widespread screening due to current treatment limitations. The tests could transform dementia care if paired with upcoming preventive therapies expected in 2027.

Scientists are refining algorithms to predict individual risk, incorporating factors like age and genetics. ALZpath's test, developed by Banner Alzheimer's Institute, is already FDA-approved for symptomatic diagnosis. Yet, the tests' utility for asymptomatic screening is limited by uncertainty about whether detected plaques will cause cognitive decline. Lifestyle interventions may help lower tau levels, but no proven treatments exist yet. The market for these tests is nascent, with direct-to-consumer options emerging despite expert reservations.

Clinical trials testing anti-amyloid drugs aim to prevent tau tangles and cognitive decline. If successful, early detection via blood tests could become standard, similar to cancer screenings. Until then, the tests serve best for confirming Alzheimer's in symptomatic patients, with significant implications for clinical trial recruitment and future preventative medicine strategies.